Patents Assigned to Pfizer Inc.
  • Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
    Patent number: 11884634
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: January 30, 2024
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
    Patent number: 11884635
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: January 30, 2024
    Assignee: PFIZER INC.
    Inventors: Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20240018244
    Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
    Type: Application
    Filed: August 15, 2023
    Publication date: January 18, 2024
    Applicant: Pfizer Inc.
    Inventors: James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
  • CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
    Publication number: 20240018258
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
  • THERAPEUTIC ANTIBODIES AND THEIR USES
    Publication number: 20240018252
    Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Applicant: PFIZER INC.
    Inventors: Tracy Chia-Chien KUO, Javier Fernando CHAPARRO RIGGERS, Wei CHEN, Amy Shaw-Ru CHEN, Edward Derrick PASCUA, Thomas John VAN BLARCOM, Leila Marie BOUSTANY, Weihsien HO, Yik Andy YEUNG, Pavel STROP, Arvind RAJPAL
  • SYSTEM AND METHOD FOR NEEDLE HIDING IN INJECTORS
    Publication number: 20240017019
    Abstract: An injector, comprising a housing arranged along a longitudinal axis and configured to receive a medicament cartridge; an injection drive mechanism for driving a piston, the piston forming part of the medicament cartridge, the injection drive mechanism injecting a medicament when the piston is forwardly displaced; and a needle hiding element, which is slidably attached to the housing and positionable in at least one of an extended orientation and a retracted orientation, wherein in the extended orientation the needle hiding element protrudes forwardly from the housing and in the retracted orientation, the needle hiding element is locked relative to the housing.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 18, 2024
    Applicant: PFIZER, INC.
    Inventors: Ilan KACHLER, Idan NAAMAN, Amotz PORAT, Tom SHEFER
  • Cell culture process for producing RSV F protein
    Publication number: 20240016915
    Abstract: The invention relates to methods for producing an RSV F protein trimer in a fed batch cell culture.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Shelby Hutchins BREEN, Cameron Albert HARRINGTON, Michaela Evelina JACOBS, Jason Arnold LOTVIN, Bhanu Chandra MULUKUTLA, David STEAD, Madhuresh SUMIT
  • Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
    Patent number: 11872274
    Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
    Type: Grant
    Filed: March 6, 2021
    Date of Patent: January 16, 2024
    Assignee: Pfizer Inc.
    Inventors: Emilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-Ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20240010731
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 11, 2024
    Applicants: Debiopharm International S.A., Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN
    Publication number: 20240009296
    Abstract: Self-amplifying RNA (saRNA) molecules encoding an influenza virus antigen and methods of use thereof are disclosed herein.
    Type: Application
    Filed: July 6, 2023
    Publication date: January 11, 2024
    Applicant: PFIZER INC.
    Inventors: Hui Cai, Ye Che, Fernando Martin Diaz, Raquel Munoz-Moreno, Alicia Solórzano Quijano, Chong Wang
  • IL-12 Variants and Uses Thereof
    Publication number: 20240010696
    Abstract: IL-12 variants are provided. Also provided are antibodies that specifically bind to PD1. Also provided are fusion proteins of IL-12 variants and anti-PD1 antibodies. Also provided are uses of these IL-12 variants, anti-PD1 antibodies, fusion proteins, and related compositions and methods.
    Type: Application
    Filed: June 15, 2023
    Publication date: January 11, 2024
    Applicant: Pfizer Inc.
    Inventors: James Reasoner APGAR, Javier Fernando CHAPARRO RIGGERS, Ling Hon Matthew CHU, Tzu-Hsuan HUANG, Kritika MOHAN, Lidia MOSYAK, Edward Derrick PASCUA, James Travis PATTERSON, Gabriel Roy STARBECK-MILLER, Dirk Michael ZAJONC
  • Diacylglycerol acyl transferase 2 inhibitors
    Patent number: 11866425
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 9, 2024
    Assignee: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS
    Publication number: 20240002384
    Abstract: The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
    Type: Application
    Filed: September 18, 2023
    Publication date: January 4, 2024
    Applicant: Pfizer Inc.
    Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS, Jennifer Lynn FULTON
  • COMBINATION THERAPY
    Publication number: 20240000783
    Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
    Type: Application
    Filed: August 10, 2021
    Publication date: January 4, 2024
    Applicants: Pfizer Inc., Astellas Pharma Inc.
    Inventors: Lars ANDERS, Kimberly Hyunjung KIM, Danan LI, Elizabeth Anne MCMILLAN, Robert Andrew ROLLINS, Brendan Ayers VEENEMAN
  • GLP-1 receptor agonists and uses thereof
    Patent number: 11858916
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: January 2, 2024
    Assignee: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Human cytomegalovirus GB polypeptide
    Patent number: 11857622
    Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: January 2, 2024
    Assignee: Pfizer Inc.
    Inventors: Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
  • Interferon beta antibodies and uses thereof
    Patent number: 11858986
    Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: January 2, 2024
    Assignees: Pfizer Inc., The Brigham And Women's Hospital, Inc.
    Inventors: Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
  • TALAZOPARIB SOFT GELATIN CAPSULE DOSAGE FORM
    Publication number: 20230414522
    Abstract: A pharmaceutical soft gelatin capsule dosage form comprising a soft gelatin shell and a fill, wherein: (a) the soft gelatin shell comprises gelatin and at least one plasticizer; and (b) the fill comprises an anti-oxidant, at least one solvent, and talazoparib or a pharmaceutically acceptable salt thereof. Said pharmaceutical composition for use in treating cancer.
    Type: Application
    Filed: November 11, 2021
    Publication date: December 28, 2023
    Applicant: PFIZER INC.
    Inventors: Alan Francis CARMODY, Lydie Claude Sylvie PAIRET
  • CELL CULTURE PROCESS
    Publication number: 20230416674
    Abstract: A cell culture medium comprising tyrosine at a concentration of at least 3 mM and polyvinylalcohol (PVA).
    Type: Application
    Filed: August 31, 2023
    Publication date: December 28, 2023
    Applicant: Pfizer Inc.
    Inventors: Bruno FIGUEROA, Yen-Tung Luan, Wenge Wang
  • SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF
    Publication number: 20230406827
    Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
    Type: Application
    Filed: January 20, 2023
    Publication date: December 21, 2023
    Applicant: Pfizer Inc.
    Inventors: Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE